Showing 3151-3160 of 20899 results for "".
- NephCure Announces First-Ever IgA Nephropathy (IgAN) Awareness Day on September 26, 2024https://reachmd.com/news/nephcure-announces-first-ever-iga-nephropathy-igan-awareness-day-on-september-26-2024/2468134/PHILADELPHIA, Sept. 3, 2024 /PRNewswire/ -- NephCure, a leading nonprofit organization dedicated to finding better treatments and a cure for rare kidney disease, is proud to announce the inaugural IgA Nephropathy (IgAN) Awareness Day on September 26, 2024. The event is specifically dedicated to r
- FDA Issues 'Letter of Support' Encouraging Use of Synuclein-based Biomarker, αSyn-SAA, in Clinical Trials in Parkinson's and Related Diseaseshttps://reachmd.com/news/fda-issues-letter-of-support-encouraging-use-of-synuclein-based-biomarker-syn-saa-in-clinical-trials-in-parkinsons-and-related-diseases/2468121/U.S. regulatory agency recognizes potential of alpha-synuclein seed amplification assay (αSyn-SAA) to accelerate clear outcomes in drugmakers' trials following multi-stakeholder collaboration amongst The Michael J. Fox Foundation for Parkinson's Research and the Critical Path Ins
- Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathyhttps://reachmd.com/news/travere-therapeutics-announces-full-fda-approval-of-filspari-sparsentan-the-only-non-immunosuppressive-treatment-that-significantly-slows-kidney-function-decline-in-iga-nephropathy/2468133/Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (N
- How Newly Identified Biomarkers Could Reveal Risk Factors for Sudden Infant Death Syndromehttps://reachmd.com/news/how-newly-identified-biomarkers-could-reveal-risk-factors-for-sudden-infant-death-syndrome/2468127/Credit: CC0 Public Domain Researchers at UC San Francisco are getting closer to being able to predict sudden infant death sy
- How the Brain's Inner Chamber Governs Our State of Consciousnesshttps://reachmd.com/news/how-the-brains-inner-chamber-governs-our-state-of-consciousness/2468135/Schematic illustration of the primary conclusion. Credit: Nature Communications (2024). DOI: 10.1038/s41467-024-51837-1
- Lebrikizumab Shows Significant Improvement in Atopic Dermatitishttps://reachmd.com/news/lebrikizumab-shows-significant-improvement-atopic-dermatitis/2468116/Lebrikizumab monotherapy showed significant improvements in clinical signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis over 16 weeks, according to new research. The analysis of two phase 3 placebo-controlled studies (ADvocate1 and ADvocate2) looked
- American Football Head Impacts Tied to Increased Brain Damage and Cognitive Declinehttps://reachmd.com/news/american-football-head-impacts-tied-to-increased-brain-damage-and-cognitive-decline/2468097/Study reveals that impaired brain clearance, indicated by larger perivascular space volume, may be the missing link between repetitive head impacts and cognitive decline in former American football players.
- Pancreatic Cancer Study Finds Most Early Staging Is Inaccuratehttps://reachmd.com/news/pancreatic-cancer-study-finds-most-early-staging-is-inaccurate/2468092/Pancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer Institute Staging of
- Light Pollution at Night May Increase Risk of Alzheimer’s, Study Findshttps://reachmd.com/news/light-pollution-at-night-may-increase-risk-of-alzheimers-study-finds/2468107/New research claims that exposure to outdoor light at night may increase the prevalence of Alzheimer’s disease, especially in people under the age of 65.The researchers who conducted the study, funded by
- 100x Improvement in Sight Seen After Gene Therapy Trialhttps://reachmd.com/news/100x-improvement-in-sight-seen-after-gene-therapy-trial/2468109/Artur Cideciyan, PhD, (left) and Tomas S. Aleman, MD (right). PHILADELPHIA— The vision of people with a rare inherited condition that causes them to lose much of their sight early in childhood was 100 times